INGR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Ingredion is a good buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock is trading near support in pre-market, fundamentals are improving, hedge funds are buying, and the upcoming earnings release could act as a near-term catalyst. While the technical trend is still bearish, the broader setup supports buying now rather than waiting for a perfect entry, especially given the investor is impatient and wants a long-term position.
INGR is still in a weak short-term technical trend: MACD histogram is negative and expanding, RSI_6 is around 31.8, and moving averages are bearish with SMA_200 > SMA_20 > SMA_5. However, the price at 112.02 is very close to key support at 111.51 and above the next support at 110.33, while pivot resistance sits at 113.42. This suggests the stock is trading near a decision zone, but not in a strong downtrend collapse. For a long-term buyer, the current level is acceptable as an entry near support.
["Hedge funds are buying, with buying up 137.50% over the last quarter.", "Upcoming QMAR 2026 earnings on 2026-05-05 pre-market could be a catalyst.", "Analysts remain generally constructive overall, with Benchmark initiating Buy and $130 target.", "Benchmark sees Ingredion benefiting from health & wellness and affordability trends.", "Options positioning is supportive, with low put-call ratios."]
["No recent news in the last week, so there is no fresh positive event momentum.", "Recent analyst action shows some caution, including Oppenheimer lowering its target to $126 and UBS lowering to $122.", "Q4 revenue declined 2.39% YoY and gross margin fell 1.88% YoY.", "Technical trend remains bearish, with MACD negative and moving averages stacked unfavorably.", "No recent congress trading data or insider buying signal to add confirmation."]
In Q4 2025, Ingredion showed mixed but improving profitability. Revenue declined 2.39% YoY to $1.757B, but net income rose 73.68% YoY to $165M and EPS jumped 79.72% YoY to 2.57. Gross margin slipped to 24.47% from a year ago, so top-line growth is still soft, but earnings power improved materially. For a long-term investor, the latest quarter was stronger on profits than sales.
Wall Street sentiment is mixed to mildly positive. Benchmark initiated coverage with a Buy and $130 target, citing durable long-term earnings growth and a compelling entry point. Oppenheimer and UBS are more cautious, with targets trimmed to $126 and $122 respectively, though both retained constructive/neutral views. Barclays also raised its target to $128 after Q4. Overall, pros see a long-term value and income story, while the cautious camp is focused on near-term headwinds and uneven Q4 execution.
